Compliance Perspectives: PAMA Pitfalls & Survival Strategies

Email not displaying correctly? View it in your browser.

January 1, 2019

HEALTH CARE REFORM
Compliance Perspectives: PAMA Pitfalls & Survival Strategies
From - Lab Compliance Advisor
PAMA's deep Medicare reimbursement cuts have had a devastating impact on the lab industry. Recent CMS changes in the 2019 Final Rule should…
Read More

INFORMATICS
Big Data Can Reshape Lab Reference Values in the Era of Personalized Medicine
From - Diagnostic Testing & Emerging Technologies
As might be expected, there are substantial differences in "normal" laboratory values determined by healthy outpatients and critically ill patients in…
Read More

CMS
Post-PAMA: Government Report Warns of Medicare Overspending(!) for Lab Tests
From - National Intelligence Report
As if the deep price cuts inflicted by PAMA weren't infuriating enough, now the US Government Accountability Office (GAO) is claiming that…
Read More

INDUSTRY BUZZ
FDA Watch: First NGS Residual Cancer Detection Test Wins Approval
From - Laboratory Industry Report
The FDA broke new ground by allowing marketing of Adaptive Biotechnologies' ClonoSEQ assay, a next generation sequencing (NGS)-based test for…
Read More

For questions concerning delivery of this email, please contact customer service at:
(888) 729-2315 | customerservice@plainlanguagemedia.com

Unsubscribe | Forward to a Friend | Update Preferences